Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review

Table 3 Primary prevention of cancer-associated venous thromboembolic event in gastrointestinal cancers

Study	Cancer	n	VTE placebo	VTE LMWH	VTE U-LMWH	RR
PROTECHT1	Gastorintestinal2	148/272	2.7%	1.5%		-44%
Agnelli et al[68], 2009	Pancreas	17/36	5.9%	8.3%		40%
SAVE-ONCO	Colo-rectal	461/464	2.0%		1.1%	-45%
Agnelli et al[69], 2012	Pancreas	128/126	10.9%		2.4%	-78%
	Stomach	207/204	1.9%		0.5%	-75%
FRAGEM	Pancreas	60/63	23%	3.4%		-85%
Maraveyas et al[70], 2012
CONKO 004	Pancreas	152/160	9.9%	1.3%		-87%
Pelzer et al[71], 2015

¹Randomization 1:2;

²Gastric (n = 40/58), colon (n = 79/156) and rectal (n = 29/58) cancers. LMWH: Low molecular weight heparin; U-LMWH: Ultra-LMWH; RR: Relative risk; VTE: Venous thromboembolic event.